Fumio Imamura

22.6k total citations · 2 hit papers
208 papers, 5.9k citations indexed

About

Fumio Imamura is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Fumio Imamura has authored 208 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 159 papers in Pulmonary and Respiratory Medicine, 129 papers in Oncology and 45 papers in Molecular Biology. Recurrent topics in Fumio Imamura's work include Lung Cancer Treatments and Mutations (120 papers), Lung Cancer Research Studies (54 papers) and Colorectal Cancer Treatments and Studies (49 papers). Fumio Imamura is often cited by papers focused on Lung Cancer Treatments and Mutations (120 papers), Lung Cancer Research Studies (54 papers) and Colorectal Cancer Treatments and Studies (49 papers). Fumio Imamura collaborates with scholars based in Japan, United States and United Kingdom. Fumio Imamura's co-authors include Toru Kumagai, Mutsuko Mukai, Masahiko Higashiyama, Kazumi Nishino, Junji Uchida, Ken Kodama, Takako Inoue, Kiyoko Shinkai, Jiro Okami and Kikuya Kato and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Fumio Imamura

194 papers receiving 5.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study

2018 269 citations Suresh S. Ramalingam, Fumio Imamura et al. Annals of Oncology profile →
Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer

2023 130 citations Juliann Chmielecki, Jhanelle E. Gray et al. Nature Communications profile →

Peers

Countries citing papers authored by Fumio Imamura

Since Specialization

Citations

This map shows the geographic impact of Fumio Imamura's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fumio Imamura with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fumio Imamura more than expected).

Fields of papers citing papers by Fumio Imamura

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fumio Imamura. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fumio Imamura. The network helps show where Fumio Imamura may publish in the future.

Co-authorship network of co-authors of Fumio Imamura

This figure shows the co-authorship network connecting the top 25 collaborators of Fumio Imamura. A scholar is included among the top collaborators of Fumio Imamura based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fumio Imamura. Fumio Imamura is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Apocrine carcinoma of the breast: distinctive metabolic reprogramming and high‐frequency PIK3CA mutations revealed by molecular and immunohistochemical analysis 2025 ·Histopathology ·Harumi Nakamura, Yoji Kukita, Nobuyoshi Kittaka, (unknown), Takahiro Nakayama, Yasuhiro Tamaki, Kenichi Yoshida, Kei Kunimasa, Fumio Imamura, Toshinari Yagi	0
2	Late-onset and relapsed cytokine release syndrome after nivolumab treatment in a patient with head and neck squamous cell carcinoma: a case report 2025 ·Frontiers in Oncology ·Tomoyuki Otsuka, (unknown), Fumio Imamura, (unknown), (unknown), Takashi Fujii, Toshihiro Kudo	0
3	Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer breakdown → 2023 ·Nature Communications ·Juliann Chmielecki, Jhanelle E. Gray, Ying Cheng, Yuichiro Ohe, Fumio Imamura, Byoung Chul Cho, Meng‐Chih Lin, Margarita Majem, Riyaz Shah, Yuri Rukazenkov, (unknown), Aleksandra Markovets, J. Carl Barrett, Ryan J. Hartmaier, Suresh S. Ramalingam	130
4	Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC 2022 ·Scientific Reports ·Kei Kunimasa, Kazumi Nishino, Yoshiharu Sato, Masahide Mori, Shôichi Ihara, Hidekazu Suzuki, Izumi Nagatomo, Toru Kumagai, Toshitaka Morishima, Fumio Imamura	5
5	Cardiac Adverse Events in EGFR-Mutated Non-Small Cell Lung Cancer Treated With Osimertinib 2020 ·JACC CardioOncology ·Kei Kunimasa, (unknown), Toru Oka, Makiko Oboshi, Madoka Kimura, Takako Inoue, Motohiro Tamiya, Tatsuya Nishikawa, Taku Yasui, Wataru Shioyama, Kazumi Nishino, Fumio Imamura, Toru Kumagai, Masashi Fujita	58
6	Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunction 2020 ·Lung Cancer ·Kei Kunimasa, Toru Oka, Satoshi Hara, Noriyuki Yamada, Satoshi Oizumi, Yoshihiro Miyashita, (unknown), (unknown), Hayato Kawachi, Takahisa Kawamura, Takako Inoue, Hanako Kuhara, Motohiro Tamiya, Kazumi Nishino, Takashi Matsunaga, Fumio Imamura, Masashi Fujita, Toru Kumagai	24
7	Infectious pericarditis caused by Gemella sanguinis induced by Endobronchial Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA): A case report 2020 ·Respiratory Medicine Case Reports ·Takako Inoue, Tatsuya Nishikawa, Kei Kunimasa, Motohiro Tamiya, Hanako Kuhara, Kazumi Nishino, Mamoru Fujiwara, Masashi Fujita, Fumio Imamura, Toru Kumagai	6
8	P2.16-19 Real World Data in Non-Small Cell Lung Cancer with Activating EGFR Mutation - A Multicenter Observational Study 2019 ·Journal of Thoracic Oncology ·Masashi Kimura, Kazumi Nishino, Yukihiro Yano, (unknown), Hidemi Suzuki, T. Hirashima, Seigo Minami, K. Komuta, Takayuki Shiroyama, Izumi Nagatomo, Fumio Imamura	0
9	Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations 2018 ·Lung Cancer ·Ken Uchibori, Miyako Satouchi, Naoko Sueoka‐Aragane, Yoshiko Urata, Akemi Sato, Fumio Imamura, Takako Inoue, Motoko Tachihara, Kazuyuki Kobayashi, Nobuyuki Katakami, (unknown), Tomonori Hirashima, Kentaro Iwanaga, Masahide Mori, Keisuke Aoe, Satoshi Morita, Shunichi Negoro	13
10	HER3 expression is enhanced during progression of lung adenocarcinoma without EGFR mutation from stage 0 to IA1 2018 ·Thoracic Cancer ·Toru Kumagai, Yasuhiko Tomita, Shin‐ichi Nakatsuka, Madoka Kimura, Kei Kunimasa, Takako Inoue, Motohiro Tamiya, Kazumi Nishino, (unknown), Takashi Kusu, Toshiteru Tokunaga, Jiro Okami, Masahiko Higashiyama, Fumio Imamura	9
11	High‐throughput screening in colorectal cancer tissue‐originated spheroids 2018 ·Cancer Science ·Jumpei Kondo, (unknown), Hiroko Endo, Kanami Yamazaki, Norio Tanaka, Yoji Kukita, Hiroaki Okuyama, Jiro Okami, Fumio Imamura, Masayuki Ohue, Kikuya Kato, Taisei Nomura, Arihiro Kohara, Seiichi Mori, Shingo Dan, Masahiro Inoue	102
12	Downregulation of EGFR in a metastatic brain lesion of EGFR-mutated non-small cell lung cancer using a tyrosine kinase inhibitor: A case report 2017 ·Oncology Letters ·Masatoshi Takagaki, Manabu Kinoshita, Kazumi Nishino, Masakazu Nakano, Hiroko Adachi, Morio Ueno, Masanori Kitamura, Yasunori Fujimoto, Kei Tashiro, Yasuhiko Tomita, Fumio Imamura, Toshiki Yoshimine	1
13	Phase I study of TAS-121, a novel third-generation epidermal growth factor receptor (EGFR) inhibitor, in patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC) 2017 ·Annals of Oncology ·Haruyasu Murakami, Yuichiro Ohe, Toyoaki Hida, Hiroshi Sakai, Kazuo Kasahara, Fumio Imamura, Tomohisa Baba, Kaoru Kubota, Yukio Hosomi, Tsuneo Shimokawa, Hidetoshi Hayashi, Kazutaka Miyadera, Tomohide Tamura, Makoto Nishio	1
14	Oncologic Outcomes of Segmentectomy Versus Lobectomy for Clinical T1a N0 M0 Non-Small Cell Lung Cancer 2015 ·The Annals of Thoracic Surgery ·Ken Kodama, Masahiko Higashiyama, Jiro Okami, Toshiteru Tokunaga, Fumio Imamura, Tomio Nakayama, Atsuo Inoue, Keiko Kuriyama	104
15	Quantitative Detection of EGFR Mutations in Circulating Tumor DNA Derived from Lung Adenocarcinomas 2011 ·Clinical Cancer Research ·Kazuya Taniguchi, Junji Uchida, Kazumi Nishino, Toru Kumagai, Takako Okuyama, Jiro Okami, Masahiko Higashiyama, Ken Kodama, Fumio Imamura, Kikuya Kato	250
16	Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel 2009 ·Annals of Oncology ·Ikuo Sekine, Y. Ichinose, Yutaka Nishiwaki, Nobuyuki Yamamoto, Masahiro Tsuboi, Kazuhiko Nakagawa, Tetsu Shinkai, Shunichi Negoro, Fumio Imamura, K. Eguchi, Koji Takeda, Y. Itoh, Tomohide Tamura, Nagahiro Saijo, M. Fukuoka	26
17	Endobronchial Ultrasound-guided Transbronchial Needle Aspiration for Lymph Node Staging of Lung Cancer 2007 ·Haigan ·(unknown), Kazuhiro Yasufuku, (unknown), (unknown), (unknown), (unknown), (unknown), Fumio Imamura, (unknown), Masami Sato, Takaaki Tsuchida, (unknown), Shinichiro Hayashi, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	1
18	Involvement of small GTPases Rho and Rac in the invasion of rat ascites hepatoma cells 1999 ·Clinical & Experimental Metastasis ·Fumio Imamura, Mutsuko Mukai, Masako Ayaki, (unknown), Takeshi Horai, Kiyoko Shinkai, Hiroyuki Nakamura, Hitoshi Akedo	29
19	Bone Marrow Involvement by Small Cell Lung Cancer Demonstrated by Magnetic Resonance Imaging. 1991 ·Haigan ·Keiko Kuriyama, (unknown), C Kuroda, (unknown), (unknown), Fumio Imamura, Takahiko Sakuma, Satoaki Nakamura, Harumichi Ikegami, Minoru Matsuda	3
20	Serum Requirement for in vitro Invasion by Tumor Cells 1991 ·Japanese Journal of Cancer Research ·Fumio Imamura, Takeshi Horai, Mutsuko Mukai, Kiyoko Shinkai, Hitoshi Akedo	28

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact